Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moritz Binder

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
Blood Cancer Journal|April 4, 2025
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomesAbiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, et al.
Cancer Discovery|August 27, 2024
RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal HematopoiesisNana Adjoa Ben-Crentsil, Wazim Mohammed Ismail, Maria E Balasis, et al.
Blood|July 26, 2023
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomasUdit Yadav, Shaji K Kumar, Linda B Baughn, et al.
Nature Communications|May 19, 2021
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axisRyan M Carr, Denis Vorobyev, Terra Lasho, et al.
Blood Advances|April 22, 2026
A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvementKenneth Jc Lim, Maximilian Johannes Steinhardt, Matthew J Rees, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
Blood Cancer Journal|April 4, 2025
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomesAbiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, et al.
Cancer Discovery|August 27, 2024
RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal HematopoiesisNana Adjoa Ben-Crentsil, Wazim Mohammed Ismail, Maria E Balasis, et al.
Blood|July 26, 2023
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomasUdit Yadav, Shaji K Kumar, Linda B Baughn, et al.
Nature Communications|May 19, 2021
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axisRyan M Carr, Denis Vorobyev, Terra Lasho, et al.
Blood Advances|April 22, 2026
A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvementKenneth Jc Lim, Maximilian Johannes Steinhardt, Matthew J Rees, et al.
Pageof 10